Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02518139 · ClinicalTrials.gov registry record · Phase 3
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Mylan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,060
- Enrollment target
- 1
- Study location
NCT02518139 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Mylan. The registered enrollment target is 1,060 participants, above the 622-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (70% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02518139, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,060 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
Conditions Studied
Interventions
- DRUG Tiotropium
- DRUG TD-4208
Study Locations (1)
South Carolina
- Palmetto Medical Research Associates L.L.C - Easley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,060 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02518139
The ClinicalTrials.gov registry entry for NCT02518139 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,060 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 622-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (70% higher). The listed sponsor is Mylan, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Tiotropium is the first listed.
NCT02518139 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT02518139 about?
NCT02518139 is a clinical study titled "A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
What is the current status of trial NCT02518139?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,060 participants. The study started on 2015-09. Estimated completion is 2017-06.
What conditions does trial NCT02518139 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT02518139?
The interventions under investigation include: Tiotropium (DRUG), TD-4208 (DRUG).
Who is sponsoring clinical trial NCT02518139?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02518139 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.